Dianthus Therapeutics Total Assets Growth & History (DNTH)
Dianthus Therapeutics's total assets was $530.9M for fiscal 2025.
View full Dianthus Therapeutics company overviewDianthus Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $530.9M | $156.9M | +41.95% |
| 2024 | 2024-12-31 | $374.0M | $194.6M | +108.47% |
| 2023 | 2023-12-31 | $179.4M | $96.3M | +115.86% |
| 2022 | 2022-12-31 | $83.1M | −$106.8M | −56.24% |
| 2021 | 2021-12-31 | $189.9M | $28.3M | +17.52% |
| 2020 | 2020-12-31 | $161.6M | $105,000 | +0.07% |
| 2019 | 2019-12-31 | $161.5M | $4.2M | +2.67% |
| 2018 | 2018-12-31 | $157.3M | $102.8M | +188.84% |
| 2017 | 2017-12-31 | $54.5M | — | — |
Dianthus Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.21B | $887.2M | +272.08% |
| Q1 2026 | 2026-03-31 | $1.25B | $898.3M | +257.70% |
| Q4 2025 | 2025-12-31 | $530.9M | $156.9M | +41.95% |
| Q3 2025 | 2025-09-30 | $577.4M | $223.2M | +63.01% |
| Q2 2025 | 2025-06-30 | $326.1M | −$42.9M | −11.62% |
| Q1 2025 | 2025-03-31 | $348.6M | −$33.9M | −8.86% |
| Q4 2024 | 2024-12-31 | $374.0M | $194.6M | +108.47% |
| Q3 2024 | 2024-09-30 | $354.2M | $161.8M | +84.06% |
| Q2 2024 | 2024-06-30 | $369.0M | $290.3M | +369.19% |
| Q1 2024 | 2024-03-31 | $382.5M | $299.0M | +358.36% |
| Q4 2023 | 2023-12-31 | $179.4M | $96.3M | +115.86% |
| Q3 2023 | 2023-09-30 | $192.5M | $28.3M | +17.27% |
| Q2 2023 | 2023-06-30 | $78.6M | −$96.5M | −55.10% |
| Q1 2023 | 2023-03-31 | $83.4M | −$110.9M | −57.07% |
| Q4 2022 | 2022-12-31 | $83.1M | −$106.8M | −56.24% |
| Q3 2022 | 2022-09-30 | $164.1M | −$42.1M | −20.42% |
| Q2 2022 | 2022-06-30 | $175.1M | −$45.3M | −20.54% |
| Q1 2022 | 2022-03-31 | $194.4M | $49.8M | +34.41% |
| Q4 2021 | 2021-12-31 | $189.9M | $28.3M | +17.52% |
| Q3 2021 | 2021-09-30 | $206.2M | $31.6M | +18.09% |
| Q2 2021 | 2021-06-30 | $220.4M | $29.7M | +15.55% |
| Q1 2021 | 2021-03-31 | $144.6M | $179,000 | +0.12% |
| Q4 2020 | 2020-12-31 | $161.6M | $105,000 | +0.07% |
| Q3 2020 | 2020-09-30 | $174.6M | −$2.6M | −1.46% |
| Q2 2020 | 2020-06-30 | $190.7M | −$4.7M | −2.41% |
| Q1 2020 | 2020-03-31 | $144.4M | −$3.3M | −2.20% |
| Q4 2019 | 2019-12-31 | $161.5M | $4.2M | +2.67% |
| Q3 2019 | 2019-09-30 | $177.2M | $4.4M | +2.57% |
| Q2 2019 | 2019-06-30 | $195.4M | $14.8M | +8.21% |
| Q1 2019 | 2019-03-31 | $147.7M | — | — |
| Q4 2018 | 2018-12-31 | $157.3M | $102.8M | +188.84% |
| Q3 2018 | 2018-09-30 | $172.8M | — | — |
| Q2 2018 | 2018-06-30 | $180.6M | — | — |
| Q4 2017 | 2017-12-31 | $54.5M | — | — |
Dianthus Therapeutics total assets trends
Over the last five fiscal years, Dianthus Therapeutics's total assets increased from $161.6M to $530.9M, a change of $369.3M. The latest reported quarter, Q2 2026, shows $1.21B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dianthus Therapeutics source filings ↗